Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.40 |
| ▸ | CDK2 | P24941 | 10/20 | 0.40 |
| ▸ | KDR | P35968 | 4/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3480686 | 0.86 | EGFR (0.41) | EGFRCDK2KDRJAK2AURKB | |
| SCHEMBL3480644 | 0.86 | EGFR (0.38) | EGFRCDK2KDRJAK2AURKB | |
| SCHEMBL3480880 | 0.86 | EGFR (0.39) | EGFRCDK2KDRJAK2AURKB | |
| SCHEMBL3480868 | 0.84 | EGFR (0.39) | EGFRCDK2KDRJAK2AURKB | |
| SCHEMBL3480955 | 0.84 | EGFR (0.38) | EGFRCDK2KDRJAK2AURKB | |
| SCHEMBL3480838 | 0.83 | EGFR (0.38) | EGFRCDK2KDRJAK2AURKB | |
| SCHEMBL3480845 | 0.77 | EGFR (0.42) | EGFR | |
| SCHEMBL3480728 | 0.77 | EGFR (0.42) | EGFR | |
| SCHEMBL3480710 | 0.73 | LMNA (0.32) | — | |
| SCHEMBL3480980 | 0.73 | LMNA (0.32) | CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252803-B2 | Piperidine derivatives | MERCK SHARP & DOHME CORP. (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252803-B2 | Piperidine derivatives | MERCK SHARP & DOHME CORP. (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252803-B2 | Piperidine derivatives | MERCK SHARP & DOHME CORP. (US) | 2012-08-28 | — | — | US | disclosed |
| US-20100041680-A1 | PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME CORP. | 2010-02-18 | — | — | US | disclosed |
| US-20100041680-A1 | PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME CORP. | 2010-02-18 | — | — | US | disclosed |
| US-20100041680-A1 | PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME CORP. | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041680-A1 | PIPERIDINE DERIVATIVES | PSEN1, PSEN2, APBA1 | EGFR 4050/4885CDK2 1996/4885KDR 3942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.